In 2013, a prostate-specific antigen (PSA) blood test revealed that Richard LaFrate's levels had jumped. Previously in a normal range, LaFrate's PSA was now above 6 ng/mL, indicating an elevated ...

Oligometastatic hormone-sensitive prostate cancer (omHSPC) represents a favorable and potentially curable disease state in which metastasis-directed therapy (MDT) improves outcomes. The combination of ...

Focal therapy (FT) is gaining ground as a viable option for treating localized prostate cancer, offering a middle path between active surveillance and radical interventions such as radical ...

Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data. Among patients with metastatic hormone-sensitive prostate cancer, the ...

Early findings show efficacy of water vapor therapy for treating intermediate-risk prostate cancer with minimal procedural ...